Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers
- 1 October 1996
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 16 (10) , 759-764
- https://doi.org/10.1089/jir.1996.16.759
Abstract
The pharmacokinetics and pharmacodynamics of recombinant human interferon-beta (rHuIFN-β1a) were assessed following administration to 12 healthy male volunteers. Each subject received, in a double-blind, balanced, random-order, crossover sequence, single doses of 6 MIU of rHuIFN-β1a (Rebif) i.V., i.m., and s.c. or matching placebo on four occasions separated by washout periods of 1 week. Blood samples were collected at preset times for the measurement of serum IFN-β levels and of intracellular 2′-5′-oligoadenylate synthetase levels. Blood pressure, sitting heart rate, respiratory rate, oral body temperature, and tolerance were monitored regularly. All administrations of rHuIFN-β1a were well tolerated, although about half of the subjects had a flu-like syndrome, as expected. After i.v. bolus injection, the pharmacokinetics of rHuIFN-βla were well described by a classic two-compartment model. Mean total clearance of rHuIFN-β1a was about 100 L.h-1. The distribution half-life was 5 min, and the terminal half-life was approximately 5 h. After i.m. or s.c. injection, serum IFN-β profiles were rather flat, and about one sixth of the administered dose was available systemically. Extent and duration of clinical and biologic effects were independent of the route of administration and of the IFN-β serum levels. Biologic pharmacodynamic effects persisted even when IFN-β serum levels had returned to baseline and were still significantly elevated 3 days after a single dose. Because of the independence of the extent and duration of clinical and biologic pharmacodynamic effects from the route of administration and from the IFN-β serum levels, the s.c. route of administration is preferred in indications in which primarily an immunomodulatory action is sought. Predominantly antiviral and antiproliferative activity is enhanced by the i.v. route to provide adequate drug levels at the site of pathology, although its application is limited on practical grounds.Keywords
This publication has 16 references indexed in Scilit:
- Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-βJournal of Interferon Research, 1992
- Biochemical and immunological responses of hairy cell leukemia patients to interferonβCancer Immunology, Immunotherapy, 1991
- Basal and Interferon-Induced 2′,5′-01igoadenylate Synthetase in Human Monocytes, Lymphocytes, and Peritoneal MacrophagesJournal of Interferon Research, 1990
- Biological and Clinical Effects of Interferon-βserat Two DosesJournal of Interferon Research, 1990
- Biochemical Host Response to Interferon-βJournal of Interferon Research, 1988
- The Lymphatic Route. V. Distribution of Human Natural Interferon-β in Rabbit Plasma and LymphJournal of Interferon Research, 1988
- Clinical and Biological Effects of Recombinant Interferon-β Administered Intravenously Daily in Phase I TrialJournal of Interferon Research, 1988
- INTERFERONS AND THEIR ACTIONSAnnual Review of Biochemistry, 1987
- Interferon-activated genesTrends in Biochemical Sciences, 1986
- INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATAThe Lancet, 1984